MCID: PLM014
MIFTS: 55

Pleomorphic Adenoma

Categories: Cancer diseases, Gastrointestinal diseases, Endocrine diseases

Aliases & Classifications for Pleomorphic Adenoma

MalaCards integrated aliases for Pleomorphic Adenoma:

Name: Pleomorphic Adenoma 12 15
Mixed Tumor, Not Otherwise Specified 73
Mixed Tumor of the Salivary Gland 12
Mixed Salivary Gland Tumor 73
Adenoma, Pleomorphic 44
Adenoma Pleomorphic 55

Classifications:



External Ids:

Disease Ontology 12 DOID:452
MeSH 44 D008949
NCIt 50 C35691 C8602
SNOMED-CT 68 8360001

Summaries for Pleomorphic Adenoma

Disease Ontology : 12 A gastrointestinal benign neoplasm that is a located in the salivary glands.

MalaCards based summary : Pleomorphic Adenoma, also known as mixed tumor, not otherwise specified, is related to pleomorphic adenoma carcinoma and salivary gland adenoma, pleomorphic. An important gene associated with Pleomorphic Adenoma is PLAG1 (PLAG1 Zinc Finger), and among its related pathways/superpathways are Development EGFR signaling pathway and DNA Damage. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include the salivary gl, salivary gland and uterus, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 76 Pleomorphic adenoma is a common benign salivary gland neoplasm characterised by neoplastic proliferation... more...

Related Diseases for Pleomorphic Adenoma

Diseases related to Pleomorphic Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 247)
# Related Disease Score Top Affiliating Genes
1 pleomorphic adenoma carcinoma 33.8 ERBB2 TP53
2 salivary gland adenoma, pleomorphic 32.9 HMGA2 PLAG1 S100B
3 adenoma 32.0 PLAG1 PLAGL1 PLAGL2 TP53
4 epithelial-myoepithelial carcinoma 31.1 HMGA2 KRT14 TP53
5 nodular hidradenoma 30.7 MUC1 VIM
6 fasciitis 30.6 ACTC1 MUC1 VIM
7 neurilemmoma 30.6 GFAP S100B VIM
8 mucoepidermoid carcinoma 30.3 ERBB2 KRT14 MUC1 TP63
9 in situ carcinoma 30.3 ERBB2 KRT14 TP53
10 rhabdoid cancer 30.3 ACTC1 MUC1 VIM
11 mesenchymoma 30.2 HMGA2 MDM2
12 myxoid liposarcoma 30.0 HMGA2 MDM2 TP53
13 chordoma 30.0 GFAP MUC1 S100B TP53 VIM
14 spindle cell lipoma 29.9 ACTC1 MDM2 VIM
15 liposarcoma 29.7 HMGA2 MDM2 TP53 VIM
16 hemangiopericytoma, malignant 29.2 ACTC1 MDM2 MUC1 S100B VIM
17 syringoma 28.8 GFAP MUC1 S100B SERPINB5 TP63 VIM
18 myoepithelioma 28.6 ACTC1 GFAP KRT14 S100B SERPINB5 TP63
19 polymorphous low-grade adenocarcinoma 28.6 ACTC1 MUC1 S100B SERPINB5 TP63 VIM
20 adenoid cystic carcinoma 27.5 ACTC1 ERBB2 KRT14 MUC1 S100B SERPINB5
21 mixed lacrimal gland cancer 11.5
22 frontal convexity meningioma 11.0 GFAP TP53
23 hydromyelia 11.0 S100B VIM
24 gliofibroma 10.9 GFAP TP53
25 bednar tumor 10.9 S100B VIM
26 localized hypertrophic neuropathy 10.9 MUC1 S100B
27 sclerosing perineurioma 10.9 MUC1 S100B
28 primitive neuroectodermal tumor of the cervix uteri 10.9 GFAP VIM
29 cerebral convexity meningioma 10.9 GFAP TP53
30 protoplasmic astrocytoma 10.9 GFAP TP53
31 primary hepatic neuroendocrine carcinoma 10.9 S100B VIM
32 cellular ependymoma 10.9 GFAP TP53
33 reticular perineurioma 10.9 MUC1 S100B
34 gemistocytic astrocytoma 10.9 GFAP S100B
35 gallbladder squamous cell carcinoma 10.9 ERBB2 TP53
36 gastric papillary adenocarcinoma 10.9 ERBB2 TP53
37 malignant peritoneal mesothelioma 10.8 MUC1 VIM
38 rhabdoid meningioma 10.8 GFAP VIM
39 uterine corpus serous adenocarcinoma 10.8 ERBB2 TP53
40 papillary tumor of the pineal region 10.8 MUC1 VIM
41 non-functioning pituitary adenoma 10.8 MUC1 S100B
42 breast mucoepidermoid carcinoma 10.8 ERBB2 MUC1
43 lymphangiectasis 10.8 ACTC1 VIM
44 central nervous system primitive neuroectodermal neoplasm 10.8 GFAP TP53
45 epithelioid malignant peripheral nerve sheath tumor 10.8 MUC1 S100B
46 breast scirrhous carcinoma 10.8 ERBB2 MUC1
47 malignant mixed mullerian tumor 10.8 MUC1 VIM
48 glomangiomyoma 10.8 ACTC1 VIM
49 angiolipoma 10.7 ACTC1 VIM
50 ependymoblastoma 10.7 GFAP TP53 VIM

Graphical network of the top 20 diseases related to Pleomorphic Adenoma:



Diseases related to Pleomorphic Adenoma

Symptoms & Phenotypes for Pleomorphic Adenoma

GenomeRNAi Phenotypes related to Pleomorphic Adenoma according to GeneCards Suite gene sharing:

26 (show all 25)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.84 S100B
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.84 VIM
3 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.84 PLAGL2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.84 PLAG1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.84 PLAGL2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.84 PLAGL2 VIM
7 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.84 PLAG1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.84 ERBB2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.84 ERBB2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.84 ERBB2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.84 VIM
12 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.84 VIM
13 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.84 VIM
14 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.84 VIM
15 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.84 PLAG1 ERBB2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.84 PLAGL2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.84 VIM
18 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.84 VIM
19 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.84 ERBB2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.84 PLAG1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.84 PLAGL2 S100B VIM ERBB2 PLAG1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.84 PLAGL2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.84 PLAGL2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.84 S100B VIM ERBB2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.84 PLAG1

MGI Mouse Phenotypes related to Pleomorphic Adenoma:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.25 TP53 PLAGL1 TP63 MDM2 SERPINB5 GFAP
2 growth/size/body region MP:0005378 10.23 PLAG1 PLAGL1 TP63 PLAGL2 SERPINB5 TP53
3 cardiovascular system MP:0005385 10.22 TP53 PLAGL1 TP63 MYOZ2 GFAP AR
4 homeostasis/metabolism MP:0005376 10.21 TP53 PLAGL2 TP63 S100B MDM2 MYOZ2
5 embryo MP:0005380 10.13 PLAG1 PLAGL1 TP63 SERPINB5 TP53 ERBB2
6 mortality/aging MP:0010768 10.13 PLAGL1 TP63 PLAGL2 SERPINB5 TP53 MYOZ2
7 digestive/alimentary MP:0005381 10.1 TP63 PLAGL2 TP53 AR KRT14 ERBB2
8 integument MP:0010771 10.01 TP53 PLAGL1 TP63 S100B MDM2 AR
9 muscle MP:0005369 9.91 TP63 TP53 MYOZ2 ERBB2 MDM2 ACTC1
10 limbs/digits/tail MP:0005371 9.85 TP53 PLAGL1 MDM2 AR ERBB2 TP63
11 neoplasm MP:0002006 9.63 TP53 TP63 MDM2 AR KRT14 ERBB2
12 normal MP:0002873 9.61 TP63 S100B SERPINB5 TP53 AR ERBB2
13 reproductive system MP:0005389 9.23 PLAG1 TP53 MDM2 AR KRT14 ERBB2

Drugs & Therapeutics for Pleomorphic Adenoma

Drugs for Pleomorphic Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 77)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
3
Mechlorethamine Approved, Investigational Phase 3,Phase 2 51-75-2 4033
4
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
5 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1,Not Applicable
6 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
7 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
8
Isophosphamide mustard Phase 3,Phase 2 0
9 Alkylating Agents Phase 3,Phase 2
10 Antineoplastic Agents, Alkylating Phase 3,Phase 2
11
Gemcitabine Approved Phase 2 95058-81-4 60750
12
Cisplatin Approved Phase 2,Phase 1 15663-27-1 84093 441203 2767
13
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
14
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
15
Mesna Approved, Investigational Phase 2 3375-50-6 598
16
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
17
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 43805 6857599
18
Everolimus Approved Phase 2 159351-69-6 6442177
19
Docetaxel Approved, Investigational Phase 2,Phase 1 114977-28-5 148124
20
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
21
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
22
Metformin Approved Phase 2 657-24-9 14219 4091
23
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
24
nivolumab Approved Phase 2 946414-94-4
25
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
26
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
27
Nicotinamide Approved, Investigational, Nutraceutical Phase 2 98-92-0 936
28
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
29
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
30
Doxil Approved June 1999 Phase 2 31703
31
Saracatinib Investigational Phase 2 379231-04-6
32
Iniparib Investigational Phase 2 160003-66-7
33
Tremelimumab Investigational Phase 2 745013-59-6
34 Epothilones Phase 2,Phase 1
35 Immunosuppressive Agents Phase 2,Phase 1
36 Anti-Infective Agents Phase 2
37 Protein Kinase Inhibitors Phase 2,Phase 1
38 Antimetabolites Phase 2,Phase 1
39 Antiviral Agents Phase 2
40 Antimetabolites, Antineoplastic Phase 2,Phase 1
41 Epothilone B Phase 2
42
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
43 Imatinib Mesylate Phase 2 220127-57-1 123596
44 Micronutrients Phase 2
45 Mitogens Phase 2,Phase 1
46 Nicotinic Acids Phase 2
47 Topoisomerase Inhibitors Phase 2
48 Trace Elements Phase 2
49 Angiogenesis Inhibitors Phase 2,Phase 1
50 Angiogenesis Modulating Agents Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 54)
# Name Status NCT ID Phase Drugs
1 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
2 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Active, not recruiting NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
3 Quadrant Versus Superficial Parotidectomy Withdrawn NCT01607866 Phase 2, Phase 3
4 Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble - Unknown status NCT02203760 Phase 2 Pazopanib plus Gemcitabine;Pazopanib
5 Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus Completed NCT00502203 Phase 2 Carboplatin;Paclitaxel
6 Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery Completed NCT00003744 Phase 2 gemcitabine
7 Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and Carboplatin in Malignant Gynecologic Tumours Completed NCT00189410 Phase 2 Pegylated Liposomal Doxorubicin and Carboplatin
8 A Phase II Trial of Adjuvant Radiation Therapy With Ifosfamide in Patients With MMT of the Uterus Completed NCT00231842 Phase 2 Ifosfamide
9 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2 PegLiposomal Doxorubicin;Carboplatin
10 Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus Completed NCT00476086 Phase 2 Gemcitabine;Oxaliplatin
11 Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01247571 Phase 2 Pazopanib Hydrochloride
12 Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01168232 Phase 2 Ixabepilone
13 Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Completed NCT00687687 Phase 2 paclitaxel;carboplatin;BSI-201 (Iniparib)
14 Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00114218 Phase 2 Gemcitabine Hydrochloride;Docetaxel
15 Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00075400 Phase 2 imatinib mesylate
16 Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2 Thalidomide
17 Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer Completed NCT00238121 Phase 2 sorafenib tosylate
18 Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors Completed NCT00520013 Phase 2 bevacizumab;erlotinib;paclitaxel;carboplatin
19 Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer Completed NCT00511992 Phase 2 Avastin;Paclitaxel;Cisplatin
20 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
21 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
22 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed NCT00390234 Phase 2 ziv-aflibercept
23 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
24 Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients Recruiting NCT03458728 Phase 1, Phase 2 BAY806946
25 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
26 Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel? Recruiting NCT03570437 Phase 2 Paclitaxel;Cediranib;Olaparib
27 A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer Recruiting NCT03015129 Phase 2 Durvalumab;Tremelimumab
28 Vorinostat (SAHA) in Uterine Sarcoma Recruiting NCT03509207 Phase 2 Vorinostat Oral Capsule
29 Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Recruiting NCT02874430 Phase 2 Metformin Hydrochloride;Doxycycline
30 A Study of Nivolumab in Selected Uterine Cancer Patients Recruiting NCT03241745 Phase 2 Nivolumab
31 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT02101775 Phase 2 Adavosertib;Gemcitabine Hydrochloride
32 Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT00478426 Phase 2 Sunitinib Malate
33 Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)_MITO 26 Not yet recruiting NCT02993705 Phase 2 Trabectedin
34 Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Suspended NCT01935934 Phase 2 Cabozantinib S-malate
35 Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer Terminated NCT00322881 Phase 2 Paclitaxel;Carboplatin
36 Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy Terminated NCT00505492 Phase 2 Carboplatin;Cisplatin;Paclitaxel
37 Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus Terminated NCT01061606 Phase 2 temsirolimus
38 Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies Withdrawn NCT00984217 Phase 2 Panitumumab
39 Suitability of DCE-MRI for Detection of Vascular Changes After VBT Unknown status NCT01991808 Phase 1
40 A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma Unknown status NCT01454479 Phase 1 Lapatinib and ixempra
41 Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors Completed NCT00413322 Phase 1 belinostat;5-Fluorouracil (5-FU)
42 Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma Completed NCT00413075 Phase 1 oral belinostat
43 Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer Completed NCT00352300 Phase 1 Carboplatin;Paclitaxel
44 Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) Completed NCT00085358 Phase 1 carboplatin;paclitaxel;docetaxel
45 Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary Recruiting NCT03206177 Phase 1 Galunisertib;Paclitaxel;Carboplatin
46 Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT00989651 Phase 1 Carboplatin;Cisplatin;Paclitaxel;Veliparib
47 Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Not yet recruiting NCT03552471 Phase 1 Rucaparib Camsylate
48 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Suspended NCT02020707 Phase 1 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
49 Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer Unknown status NCT01367301 Not Applicable paclitaxel;carboplatin
50 Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Completed NCT01080521

Search NIH Clinical Center for Pleomorphic Adenoma

Cochrane evidence based reviews: adenoma, pleomorphic

Genetic Tests for Pleomorphic Adenoma

Anatomical Context for Pleomorphic Adenoma

The Foundational Model of Anatomy Ontology organs/tissues related to Pleomorphic Adenoma:

19
The Salivary Gl

MalaCards organs/tissues related to Pleomorphic Adenoma:

41
Salivary Gland, Uterus, Prostate, Liver, Bone, Trachea, Skin

Publications for Pleomorphic Adenoma

Articles related to Pleomorphic Adenoma:

(show top 50) (show all 847)
# Title Authors Year
1
Primary carcinoma ex-pleomorphic adenoma of anterior commissure of the larynx. ( 29980410 )
2018
2
Cripto-1 is overexpressed in carcinoma ex pleomorphic adenoma of salivary gland. ( 29594385 )
2018
3
Lacrimal gland pleomorphic adenoma and malignant epithelial tumours: clinical and imaging differences. ( 29680804 )
2018
4
Effect of Xylosyltransferase-I Silencing on Implanting Growth of Salivary Pleomorphic Adenoma. ( 29867072 )
2018
5
A rare case of atypical pleomorphic adenoma arising from periocular ectopic lacrimal gland. ( 29936687 )
2018
6
Pleomorphic adenoma of salivary glands: common and uncommon CT and MR imaging features. ( 29845358 )
2018
7
Pleomorphic adenoma of the lacrimal gland: A review with updates on malignant transformation and molecular genetics. ( 29755265 )
2018
8
Promoter hypermethylation may contribute to Ea89cadherin repression in the human salivary carcinoma ex pleomorphic adenoma. ( 29207084 )
2018
9
Complications after superficial parotidectomy for pleomorphic adenoma. ( 29924764 )
2018
10
A huge pleomorphic adenoma of the submandibular salivary gland. ( 29549132 )
2018
11
Pleomorphic adenoma of nasal septum: a rare case. ( 29592986 )
2018
12
68Ga-DOTA-TOC Uptake in Pleomorphic Adenoma. ( 29847321 )
2018
13
Epithelial-Myoepithelial Carcinoma: Frequent Morphologic and Molecular Evidence of Preexisting Pleomorphic Adenoma, Common HRAS Mutations in PLAG1-intact and HMGA2-intact Cases, and Occasional TP53, FBXW7, and SMARCB1 Alterations in High-grade Cases. ( 29135520 )
2018
14
JOURNAL CLUB: The Warthin Tumor Score: A Simple and Reliable Method to Distinguish Warthin Tumors From Pleomorphic Adenomas and Carcinomas. ( 29667889 )
2018
15
Metastasizing pleomorphic adenoma in the multiple organs: A case report on FDG-PET/CT imaging. ( 29879077 )
2018
16
Carcinosarcoma ex Pleomorphic Adenoma of the Submandibular Gland in a 64-Year-Old Man: A Case Report. ( 29540647 )
2018
17
Dedifferentiated adenoid cystic carcinoma ex pleomorphic adenoma of the parotid. ( 29893347 )
2018
18
Pleomorphic Adenoma of Submandibular Gland with Extensive Cystic Keratinization. ( 29290205 )
2018
19
Recurrent rearrangements of the PLAG1 and HMGA2 genes in lacrimal gland pleomorphic adenoma and carcinoma ex pleomorphic adenoma. ( 29437290 )
2018
20
Large Pleomorphic Adenoma of Hard Palate. ( 29963438 )
2018
21
Metastasising Pleomorphic Salivary Adenoma: A Rare Case Report of a Massive Untreated Minor Salivary Gland Pleomorphic Adenoma with Concurrent Ipsilateral Cervical Node Metastases. ( 29725854 )
2018
22
Lacrimal myoepithelial carcinoma ex recurrent pleomorphic adenoma: A clinicopathological report and review of the literature. ( 29387416 )
2018
23
Gray scale and doppler ultrasonography features of the carcinoma ex pleomorphic adenoma. ( 29365290 )
2018
24
Synchronous pleomorphic adenoma and oncocytic carcinoma in the ipsilateral parotid gland. ( 29934012 )
2018
25
The Effectiveness of Sternocleidomastoid Flap Versus Superficial Musculoaponeurotic System Flap for the Prevention of Frey Syndrome and Facial Depressed Deformity in Parotid Surgery for Pleomorphic Adenoma. ( 29095193 )
2018
26
Soft Palate Pleomorphic Adenoma of a Minor Salivary Gland: An Unusual Presentation. ( 29808148 )
2018
27
Submandibular gland pleomorphic adenoma: Histopathological capsular characteristics and correlation with the surgical outcome. ( 29689463 )
2018
28
Giant pleomorphic adenoma of the lacrimal gland: A surgical challenge. ( 29039996 )
2017
29
Largest De Novo Parapharyngeal Pleomorphic Adenoma: A Rare Case Removed Via Minimal Access Approach. ( 28713752 )
2017
30
Intracapsular carcinoma ex-pleomorphic adenoma of the parapharyngeal space: report of two cases and review of the literature. ( 29143959 )
2017
31
Clinicopathologic and Surgical Study of Pleomorphic Adenoma of the Parotid Gland: Analysis of Risk Factors for Recurrence and Facial Nerve Dysfunction. ( 28863883 )
2017
32
Parapharyngeal space pleomorphic adenoma: a case report. ( 28690748 )
2017
33
Hemifacial Spasm Secondary to Parotid Pleomorphic Adenoma With Stylomastoid Foramen Extension. ( 27755360 )
2017
34
Pleomorphic Adenoma of Minor Salivary Glands in Child. ( 29284907 )
2017
35
The Effects of Platelet-Rich Fibrin Membrane on Secondary Healing After Pleomorphic Adenoma Excision in the Hard Palate: A Preliminary Study. ( 28713740 )
2017
36
Increased SOX2 expression in salivary gland carcinoma ex pleomorphic adenoma progression: an association with adverse outcome. ( 28842747 )
2017
37
Recurrent pleomorphic adenoma: is treatment considerably delayed thus affecting surgical morbidity? ( 29141486 )
2017
38
Relapse of Pleomorphic Adenoma from Childhood to Adulthood: Case Report. ( 29590741 )
2017
39
Apurinic/apyrimidinic endonuclease 1 (APE1) is overexpressed in malignant transformation of salivary gland pleomorphic adenoma. ( 28523411 )
2017
40
The role of insulin-like growth factor I-II receptor on development of pleomorphic adenoma. ( 28625007 )
2017
41
The importance of BMP6 marker within the process of epithelial-mesenchymal transition in the pleomorphic adenoma of the salivary gland. ( 28523310 )
2017
42
Pleomorphic adenoma gene like-2 induces epithelial-mesenchymal transition via Wnt/I^-catenin signaling pathway in human colorectal adenocarcinoma. ( 28259923 )
2017
43
The recurrent pleomorphic adenoma conundrum. ( 29278551 )
2017
44
BRCA1/2 Mutations in Salivary Pleomorphic Adenoma and Carcinoma-ex-Pleomorphic Adenoma. ( 29285471 )
2017
45
A Case Report of Rare Carcinoma Ex Pleomorphic Adenoma of Submandibular Gland and its Detailed Description. ( 28658924 )
2017
46
Transnasal Endoscopic Resection of a Pleomorphic Adenoma Originate From Nasal Floor. ( 28857999 )
2017
47
Re: Endoscopically-assisted extracapsular dissection of pleomorphic adenoma of the parotid gland through a postauricular sulcus approach in young patients. ( 28735635 )
2017
48
Correlation between computed tomography imaging and histopathology in pleomorphic adenoma of parotid gland. ( 29055657 )
2017
49
Pleomorphic Adenoma of an Accessory Lacrimal Gland Masquerading as a Chalazion. ( 28645342 )
2017
50
Pleomorphic Adenoma of the Posterior Surface of the Soft Palate Causing Sleep Disturbance: A Case Report. ( 29187728 )
2017

Variations for Pleomorphic Adenoma

Cosmic variations for Pleomorphic Adenoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM43909 TP53 salivary gland,parotid,adenoma,pleomorphic c.817C>A p.R273S 17:7673803-7673803 15
2 COSM10808 TP53 salivary gland,parotid,adenoma,pleomorphic c.488A>G p.Y163C 17:7675124-7675124 15
3 COSM6932 TP53 salivary gland,parotid,adenoma,myoepithelial c.733G>A p.G245S 17:7674230-7674230 11
4 COSM43635 TP53 salivary gland,parotid,adenoma,myoepithelial c.536A>T p.H179L 17:7675076-7675076 11
5 COSM13168 CTNNB1 salivary gland,parotid,adenoma,NS c.104T>C p.I35T 3:41224616-41224616 10
6 COSM5688 CTNNB1 salivary gland,parotid,adenoma,NS c.121A>C p.T41P 3:41224633-41224633 10
7 COSM21826 ATM salivary gland,parotid,adenoma,NS c.2572T>C p.F858L 11:108267276-108267276 10

Copy number variations for Pleomorphic Adenoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 239266 8 38279166 38315052 Gain FGFR1 Pleomorphic adenoma

Expression for Pleomorphic Adenoma

Search GEO for disease gene expression data for Pleomorphic Adenoma.

Pathways for Pleomorphic Adenoma

GO Terms for Pleomorphic Adenoma

Cellular components related to Pleomorphic Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.77 ACTC1 AR ERBB2 GFAP KRT14 MDM2
2 nuclear chromatin GO:0000790 8.92 AR MUC1 TP53 TP63

Biological processes related to Pleomorphic Adenoma according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.98 AR HMGA2 PLAG1 PLAGL1 PLAGL2 TP53
2 transcription by RNA polymerase II GO:0006366 9.88 HMGA2 PLAG1 PLAGL1 PLAGL2 TP53 TP63
3 cell proliferation GO:0008283 9.85 AR ERBB2 S100B TP53 TP63
4 cellular response to hypoxia GO:0071456 9.75 MDM2 S100B TP53
5 negative regulation of apoptotic process GO:0043066 9.73 ACTC1 ERBB2 HMGA2 MDM2 TP53 TP63
6 negative regulation of neuron projection development GO:0010977 9.67 GFAP MDM2 VIM
7 astrocyte development GO:0014002 9.58 GFAP VIM
8 intermediate filament organization GO:0045109 9.57 GFAP VIM
9 prostate gland development GO:0030850 9.56 AR TP63
10 positive regulation of glial cell proliferation GO:0060252 9.55 GFAP PLAG1
11 positive regulation of transcription by RNA polymerase III GO:0045945 9.54 AR ERBB2
12 mitotic G1 DNA damage checkpoint GO:0031571 9.52 TP53 TP63
13 Bergmann glial cell differentiation GO:0060020 9.51 GFAP VIM
14 prostate gland growth GO:0060736 9.48 AR PLAG1
15 cellular response to actinomycin D GO:0072717 9.37 MDM2 TP53
16 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.33 MUC1 TP53 TP63
17 intermediate filament-based process GO:0045103 9.32 GFAP VIM
18 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.26 MDM2 MUC1 PLAGL1 TP53
19 positive regulation of gene expression GO:0010628 9.23 ACTC1 AR ERBB2 HMGA2 MDM2 PLAG1

Molecular functions related to Pleomorphic Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II transcription factor activity, sequence-specific DNA binding GO:0000981 9.91 AR HMGA2 PLAG1 PLAGL1 PLAGL2 TP53
2 identical protein binding GO:0042802 9.7 ERBB2 GFAP MDM2 S100B TP53 TP63
3 transcription regulatory region DNA binding GO:0044212 9.62 AR HMGA2 TP53 TP63
4 structural constituent of cytoskeleton GO:0005200 9.58 GFAP KRT14 VIM
5 transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding GO:0001077 9.35 AR HMGA2 PLAG1 PLAGL2 TP63
6 keratin filament binding GO:1990254 9.26 KRT14 VIM
7 p53 binding GO:0002039 8.92 MDM2 MUC1 TP53 TP63

Sources for Pleomorphic Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....